What Is New in Cytokine Research Related to Trauma/Critical Care

Journal of Intensive Care Medicine

Volumn 21, Issue 2, 2006, Pages 63-85

  Jawa, Randeep S ^a   Kulaylat, Mahmoud N ^a   Baumann, Heinz ^b   Dayton, Merril T ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

cytokine; interleukin; review; sepsis; trauma

Indexed keywords

CYTOKINE; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

BLOOD; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; HUMAN; INJURY; INTENSIVE CARE; MEDICAL RESEARCH; METABOLISM; REVIEW; SEPSIS;

BIOMEDICAL RESEARCH; CRITICAL CARE; CYTOKINES; HUMANS; INTERLEUKINS; POLYMORPHISM, GENETIC; SEPSIS; TUMOR NECROSIS FACTOR-ALPHA; WOUNDS AND INJURIES;

EID: 33746396118     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1177/0885066605284325     Document Type: Review

References (81)

1. Kumar A, Short J, Parrillo J. Genetic factors in septic shock. JAMA. 1999;282:579-581.
2. Cariou A, Chiche JD, Charpentier J, et al. The era of genomics: impact on sepsis clinical trial design. Crit Care Med. 2002;30 (suppl): S341-S348.
3. Lowe P, Galley H, Abdel-Fattah A, Webster N. Influence of interleukin-10 polymorphisms on interleukin-10 expression and survival in critically ill patients. Crit Care Med.2003;31:34-38.
4. Ness, R, Haggerty C, Harger G, Ferrell R. Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol.2004;160:1033-1038.
5. Peters DL, Barber RC, Flood EM, et al. Methodologic quality and genotyping reproducibility in studies of tumor necrosis factor -308 G-A single nucleotide polymorphism and bacterial sepsis: implications for studies of complex traits. Crit Care Med. 2003;31:1691-1696.
6. van der Poll, T., van Deventer, S. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 1999;13:413-426, ix.
7. DeLong W, Born C. Cytokines in patients with polytrauma. Clin Orthop Rel Res. 2004;1:57-65.
8. Opal SM. Clinical trial design and outcomes in patients with severe sepsis. Shock. 2003;20:295-302.
9. Lin E, Calvano SE, Lowry SF. Inflammatory cytokines and cell response in surgery. Surgery. 2000;127:117-126.
10. Cabioglu N, Bilgic S, Deniz G, et al. Decreased cytokine expression in peripheral blood leukocytes of patients with severe sepsis. Arch Surg. 2002;137:1037-1043.
11. Rau B, Baumgart K, Paszkowski AS, et al. Clinical relevance of caspase-1 activated cytokines in acute pancreatitis: high correlation of serum interleukin-18 with pancreatic necrosis and systemic complications. Crit Care Med. 2001;29:1556-1562.
12. Schonhorn J, Sharma H, Pritchard, J. ELISA Systems for the rapid quantitation of total human IL12 and human IL12 p70. J Allergy Clin Immunol. 1997;99:314.
13. Sullivan MD, Liponis T, Durda P, Pritchard J. An enzyme-linked immunosorbent assay (ELISA) for the measurement of human interleukin-8 (hIL-8) in serum, plasma and tissue culture fluids. J Allergy Clin Immunol. 1997;99:314.
14. Goebel MU, Mills PJ, Irwin MR, Ziegler MG. Interleukin-6 and tumor necrosis factor-alpha production after acute psychological stress, exercise, and infused isoproterenol: differential effects and pathways. Psychosom Med.2000;62:591-598.
15. Huhn RD, Radwanski E, Gallo J, et al. Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers. Clin Pharmacol Ther. 1997;62:171-180.
16. Kenis G, Teunissen C, De Jongh R, et al. Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. Cytokine. 2002;19:228-235.
17. Nagata T, Tobitani W, Kiriike N, et al. Capacity to produce cytokines during weight restoration in patients with anorexia nervosa. Psychosom Med. 1999;6:371-377.
18. Malone D, Napolitano LM, Genuit T, et al. Total cytokine immunoassay: a more accurate method of cytokine measurement? J Trauma. 2001;50:821-825.
19. Millo JL, Schultz MJ, Williams C, et al. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med. 2004;30:68-74.
20. Hobisch-Hagen P, Wiedermann F, Mayr A, et al. Blunted erythropoietic response to anemia in multiply traumatized patients. Crit Care Med. 2001;29:743-747.
21. Rigato O, Salomao R. Impaired production of interferon-gamma and tumor necrosis factor-alpha but not of interleukin 10 in whole blood of patients with sepsis. Shock.2003;19:113-116.
22. Maier B, Schwerdtfeger K, Mautes A, et al. Differential release of interleukins 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock. 2001;15:421-426.
23. Holmes CL, Russell JA, Walley KR. Genetic polymorphisms in sepsis and septic shock: role in prognosis and potential for therapy. Chest. 2003;124:1103-1115.
24. Majetschak M, Flohe S, Obertacke U, et al. Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg. 1999;230:207-214.
25. Riese J, Woerner K, Zimmermann P, et al. Association of a TNF[beta] gene polymorphism with complications after major abdominal operations. Shock. 2003;19:1-4.
26. Majetschak M, Obertacke U, Schade FU, et al. Tumor necrosis factor gene polymorphisms, leukocyte function, and sepsis susceptibility in blunt trauma patients. Clin Diagn Lab Immunol. 2002;9:1205-1211.
27. Tomasdottir H, Hjartarson H, Ricksten A, et al. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg. 2003;97:944-949.
28. Rauchschwalbe S, Maseizik T, Mittelkotter U, et al. Effect of the LT-[alpha] (+250 G/A) polymorphism on markers of inflammation and clinical outcome in critically ill patients. J Trauma. 2004;56:815-822.
29. Roumen RM, Hendriks T, van der Ven-Jongekrijg J, et al. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg. 1993;218:769-776.
30. Andermahr J, Greb A, Hensler T, et al. Pneumonia in multiple injured patients: a prospective controlled trial on early prediction using clinical and immunological parameters. Inflamm Res. 2002;51:265-272.
31. Spielmann S, Kerner T, Ahlers O, et al. Early detection of increased tumour necrosis factor alpha (TNFalpha) and soluble TNF receptor protein plasma levels after trauma reveals associations with the clinical course. Acta Anaesthesiol Scand. 2001;45:364-370.
32. Woiciechowsky C, Schoning B, Cobanov J, et al. Early IL-6 plasma concentrations correlate with severity of brain injury and pneumonia in brain-injured patients. J Trauma.2002;52:339-345.
33. Hayakata T, Shiozaki T, Tasaki O, et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock. 2004;22:102-107.
34. Gallagher J, Fisher C, Sherman B, et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-alpha antibody afelimomab in patients with sepsis syndrome. Intensive Care Med. 2001;27:1169-1178.
35. Reid CL, Perrey C, Pravica V, et al. Genetic variation in pro-inflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med.2002;30:2216-2221.
36. Maskin B, Fontan PA, Spinedi EG, et al. Evaluation of endotoxin release and cytokine production induced by antibiotics in patients with Gram-negative nosocomial pneumonia. Crit Care Med. 2002;30:349-354.
37. Abraham E, Laterre PF, Garbino J, et al. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients. Crit Care Med. 2001;29:503-510.
38. Marik PE, Zaloga GP, NORASEPT II Study Investigators. North American Sepsis Trial II. The effect of aging on circulating levels of proinflammatory cytokines during septic shock. Norasept II Study Investigators. J Am Geriatr Soc.2001;49:5-9.
39. Katja B, Hartmut K, Pawel M, et al. The value of immune modulating parameters in predicting the progression from peritonitis to septic shock. Shock. 2001;15:95-100.
40. Sfeir T, Saha DC, Astiz M, Rackow EC. Role of interleukin-10 in monocyte hyporesponsiveness associated with septic shock. Crit Care Med. 2001;29:129-133.
41. Gando S, Nishihira J, Kobayashi S, et al. Macrophage migration inhibitory factor is a critical mediator of systemic inflammatory response syndrome. Intensive Care Med.2001;27:1187-1193.
42. Mokart D, Capo C, Blache JL, et al. Early postoperative compensatory anti-inflammatory response syndrome is associated with septic complications after major surgical trauma in patients with cancer. Br J Surg. 2002;89:1450-1456.
43. Appoloni O, Vincent JL, Duchateau J. Response of tumour necrosis factor-alpha to delayed in vitro monocyte stimulation in patients with septic shock is related to outcome. Clin Sci (Lond). 2002;102:315-320.
44. Flohe S, Lendemans S, Selbach C, et al. Effect of granulocyte-macrophage colony-stimulating factor on the immune response of circulating monocytes after severe trauma. Crit Care Med. 2003;31:2462-2469.
45. Reinhart K, Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 2001;29(suppl): S121-S125.
46. Eichacker PQ, Parent C, Kalil A, et al. Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. Am J Respir Crit Care Med. 2002;166:1197-1205.
47. Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study. Crit Care Med.2001;29:765-769.
48. Panacek EA, Marshall JC, Albertson TE, et al. Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab’)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels. Crit Care Med.2004;32:2173-2182.
49. Dellinger, RP, McCarthy, R. New directions in research of severe sepsis: a careful analysis of the MONARCS trial. Medscape, 2001. Available at: http://www.medscape.com.
50. Schluter B, Raufhake C, Erren M, et al. Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med. 2002;30:32-37.
51. von Heymann C, Langenkamp J, Dubisz N, et al. Posttraumatic immune modulation in chronic alcoholics is associated with multiple organ dysfunction syndrome. J Trauma. 2002;52:95-103.
52. Muehlstedt SG, Richardson CJ, Lyte M, Rodriguez JL. Systemic and pulmonary effector cell function after injury. Crit Care Med. 2002;30:1322-1326.
53. Minambres E, Cemborain A, Sanchez-Velasco P, et al. Correlation between transcranial interleukin-6 gradient and outcome in patients with acute brain injury. Crit Care Med.2003;31:933-938.
54. Frati A, Salvati M, Mainiero F, et al. Inflammation markers and risk factors for recurrence in 35 patients with a post-traumatic chronic subdural hematoma: a prospective study. J Neurosurg. 2004;100:24-32.
55. Pape HC, van Griensven M, Rice J, Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma. 2001;50:989-1000.
56. Pape HC, Grimme K, Van Griensven M, Impact of intramedullary instrumentation versus damage control for femoral fractures on immunoinflammatory parameters: prospective randomized analysis by the EPOFF Study Group. J Trauma. 2003;55:7-13.
57. Bernard GR, Ely EW, Wright TJ, Safety and dose relationship of recombinant human activated protein C for coagulopathy in severe sepsis. Crit Care Med 2001;29:2051-2059.
58. Bernard GR, Vincent JL, Laterre PF, Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
59. Witthaut R, Busch C, Fraunberger P, Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med. 2003;29:1696-1702.
60. Loisa P, Rinne T, Laine S, Anti-inflammatory cytokine response and the development of multiple organ failure in severe sepsis. Acta Anaesthesiol Scand. 2003;47:319-325.
61. Pettila V, Hynninen M, Takkunen O, Kuusela P, Valtonen M. Predictive value of procalcitonin and interleukin 6 in critically ill patients with suspected sepsis. Intensive Care Med. 2002; 28: 1220-1225.
62. Wunderink R, Leeper K Jr, Schein R, Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest. 2001;119:523-529.
63. Pathan N, Hemingway CA, Alizadeh AA, Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet. 2004;363:203-209.
64. Mathiak G, Neville LF, Grass G, Chemokines and interleukin-18 are up-regulated in bronchoalveolar lavage fluid but not in serum of septic surgical ICU patients. Shock. 2001;15:176-180.
65. Wong, H. ARDS: the future. Crit Care Clin. 2002;18: 177-196.
66. Liener UC, Bruckner UB, Knoferl MW, Chemokine activation within 24 hours after blunt accident trauma. Shock. 2002;17:169-172.
67. Muehlstedt S, Lyte M, Rodriguez J. Increased IL-10 Production and HLA-DR suppression in the lungs of injured patients precede the development of nosocomial pneumonia. Shock. 2002;17:443-450.
68. Schroder O, Laun R, Held B, Ekkernkamp A, Schulte KM. Association of interleukin-10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study. Shock.2004;21:306-310.
69. Galley HF, Lowe PR, Carmichael RL, Webster NR. Genotype and interleukin-10 responses after cardiopulmonary bypass. Br J Anaesth. 2003;91:424-426.
70. Adib-Conquy M, Asehnoune K, Moine P, Cavaillon JM. Long-term-impaired expression of nuclear factor-kappa B and I kappa B alpha in peripheral blood mononuclear cells of trauma patients. J Leukoc Biol. 2001;70:30-38.
71. Hynninen M, Pettila V, Takkunen O, Predictive value of monocyte histocompatibility leukocyte antigen-DR expression and plasma interleukin-4 and -10 levels in critically ill patients with sepsis. Shock. 2003;20:1-4.
72. Kurdowska A, Noble JM, Grant IS, Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Crit Care Med. 2002;30:2335-2337.
73. Wiedermann FJ, Mayr AJ, Hobisch-Hagen P, Fuchs D, Schobersberger W. Association of endogenous G-CSF with anti-inflammatory mediators in patients with acute respiratory distress syndrome. J Interferon Cytokine Res. 2003;23:729-736.
74. Wiedermann FJ, Mayr AJ, Kaneider NC, Alveolar granulocyte colony-stimulating factor and alpha-chemokines in relation to serum levels, pulmonary neutrophilia, and severity of lung injury in ARDS. Chest. 2004;125:212-219.
75. Stuber F, Wrigge H, Schroeder S, Kinetic and reversibility of mechanical ventilation-associated pulmonary and systemic inflammatory response in patients with acute lung injury. Intensive Care Med. 2002;28:834-841.
76. Wu CL, Lee YL, Chang KM, Bronchoalveolar interleukin-1 beta: a marker of bacterial burden in mechanically ventilated patients with community-acquired pneumonia. Crit Care Med. 2003;31:812-827.
77. Iglesias J, Marik PE, Levine JS, Norasept II Study Investigators. Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis. 2003;41:62-75.
78. Simmons EM, Himmelfarb J, Sezer MT, Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004;65:1357-1365.
79. Cole L, Bellomo R, Hart G, A phase II randomized, controlled trial of continuous hemofiltration in sepsis. Crit Care Med. 2002;30:100-106.
80. Reddy, P. Interleukin-18: recent advances. Curr Opin Hematol. 2004;11:405-410.
81. Nakae H, Endo S, Inoue Y, Matrix metalloproteinase-1 and cytokines in patients with acute pancreatitis. Pancreas.2003;26:134-138.